Biologics License Application (BLA)

In Detail

A Biologics License Application (BLA) is the regulatory submission required for FDA approval of biological products — a category that includes vaccines, blood products, gene therapies, cellular therapies, monoclonal antibodies, and other treatments derived from living organisms. While the NDA covers traditional small-molecule drugs, the BLA covers biologics, which are typically larger, more complex molecules produced through biotechnology processes. The BLA submission includes comprehensive data from preclinical and clinical studies demonstrating the product's safety, purity, and potency, as well as detailed information about the manufacturing process. Manufacturing is particularly critical for biologics because they are produced by living cells, making the production process inherently more complex and variable than traditional drug manufacturing. The FDA reviews BLAs through a process similar to NDA review, with a standard timeline of 10-12 months and a priority review option of 6-8 months. The Center for Biologics Evaluation and Research (CBER) reviews most BLAs, though some therapeutic biologics are reviewed by the Center for Drug Evaluation and Research (CDER). Biologics represent a growing share of new approvals — many of the most innovative treatments in oncology, immunology, and rare diseases are biologics. The Biologics Price Competition and Innovation Act (BPCIA) created a pathway for biosimilars, which are analogous to generic drugs but for biologics. Understanding the BLA pathway is increasingly important as biologic therapies become more prevalent in clinical trials.